An Immunocompromised Mouse Model of Candida auris Systemic Infection

Methods Mol Biol. 2022:2517:317-328. doi: 10.1007/978-1-0716-2417-3_25.

Abstract

With the recent emergence of multidrug-resistant Candida auris, there is an urgent need for new antifungal compounds with novel pharmacodynamic and pharmacokinetic properties that can treat systemic fungal infections caused by this emerging yeast. Historically, testing the efficacy of treatment for disseminated candidiasis was accomplished using a diverse array of in vivo animal models, including mice which offer an advantage both in their similarities to humans and their lower cost of maintenance. However, in order to create effective in vivo models for testing new antifungal compounds designed to treat systemic infections, it is important that these models also mimic several of the relevant predisposing conditions that can lead to disseminated candidiasis. Here, we describe an immunocompromised mouse model of hematogenously disseminated C. auris infection, which may have utility to test the efficacy of candidate antifungal compounds.

Keywords: Animal model; Candida auris; Disseminated candidiasis; Mouse model.

MeSH terms

  • Animals
  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Candida auris
  • Candida*
  • Candidiasis
  • Candidiasis, Invasive* / drug therapy
  • Disease Models, Animal
  • Mice
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents

Supplementary concepts

  • Candida auris infection
  • Systemic candidiasis